Antibody-drug conjugate · Cytotoxic, directed at 5T4 oncofetal antigen (TPBG) · developed by Exelixis
XB010 is an antibody-drug conjugate in which an anti-5T4 monoclonal antibody is linked to the microtubule-disrupting agent monomethyl auristatin E (MMAE). The antibody binds the 5T4 transmembrane glycoprotein on tumor cells, and after internalization MMAE inhibits tubulin polymerization, causing G2/M arrest and apoptosis. It is being studied in solid tumors, esophageal squamous cell cancer, head and neck squamous cell cancer, non-small cell lung cancer, and breast cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06545331 | Phase 1 | Locally Advanced or Metastatic Solid Tumors | Recruiting | EXEL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Esophageal Squamous Cell CancerHead and Neck Squamous Cell CancerHormone-receptor-positive Breast CancerLocally Advanced or Metastatic Solid TumorsNSCLC (Non-small Cell Lung Cancer)Triple Negative Breast Cancer (TNBC)
Updated Nov 15, 2026. Something wrong or missing? Report it on the EXEL page.
See EXEL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
EXEL catalysts and pipeline →